Scientists Identify New Target to Halt Cholesterol Build‑Up
Unveiling the Cholesterol „Switch”
A team at the University of California, San Diego has uncovered a previously unknown mechanism that enables high‑cholesterol diets to bypass the body’s natural defenses, and demonstrated that blocking this pathway can dramatically lower harmful LDL cholesterol.
The discovery emerged from a series of experiments conducted in the UC‑SD research laboratory during 2026. Researchers examined how excess dietary cholesterol affects liver cells and found that a specific protein complex amplifies the production of LDL particles, even when the body’s usual regulatory signals are active. By inhibiting this complex with a novel small‑molecule inhibitor, the scientists were able to reduce LDL levels by up to 60 % in animal models.
Could a New Drug Replace Statins?
The team focused on a protein called SCAP, which normally helps cells sense cholesterol levels. In the presence of a high‑fat diet, SCAP becomes overactive, triggering the liver to produce more LDL. „It’s like a faulty thermostat that keeps the furnace running even when the house is already warm,” explained lead investigator Dr. Maya Patel. The new inhibitor, named SCAP‑Block, binds to SCAP’s active site, preventing it from sending the overproduction signal. In mice fed a cholesterol‑rich diet, SCAP‑Block lowered LDL cholesterol by 58 % and reduced plaque formation in arterial walls.
The findings were published in the journal Nature Medicine and suggest that targeting SCAP could complement existing statin therapy. Unlike statins, which inhibit cholesterol synthesis, SCAP‑Block works downstream, directly curbing LDL production.
The question now is whether SCAP‑Block can offer a safer or more effective alternative for patients who cannot tolerate statins. Early safety studies in rodents show no significant liver toxicity or muscle side effects, common concerns with current cholesterol drugs. However, human trials are required to confirm efficacy and safety. „We are optimistic, but we must proceed cautiously,” said Patel.
Future Directions and Public Health Impact
If successful, a SCAP‑blocking drug could provide a dual approach: reducing cholesterol synthesis and preventing the liver’s compensatory overproduction. This could be especially valuable for individuals with familial hypercholesterolemia or those who experience statin intolerance.
The research team plans to initiate phase‑I clinical trials within the next year. They also aim to investigate whether SCAP‑Block can synergize with lifestyle interventions, such as diet and exercise, to further lower cardiovascular risk. Public health experts anticipate that a new class of cholesterol‑lowering drugs could reduce heart disease incidence worldwide, particularly in populations with high dietary cholesterol intake.
What is the main advantage of SCAP‑Block over statins? SCAP‑Block targets a downstream pathway that directly limits LDL production, potentially offering benefits for patients who cannot tolerate statins or who have inadequate response to existing therapy.
Frequently Asked Questions
How soon might a SCAP‑blocking drug reach patients? Human trials are expected to begin within a year, with potential approval within five to seven years, depending on trial outcomes and regulatory review.
Will this new treatment replace dietary changes? No. While SCAP‑Block may reduce LDL levels, it does not eliminate the need for a heart‑healthy diet and regular exercise, which remain foundational for cardiovascular health.